Pharmaceutical Drug Delivery Market By Administration Route (Oral, Injectable, Topical, Ocular, Nasal, Transmucosal & Implantable, Pulmonary, Transdermal Patch), Application (Cancer, Diabetes, Cardiovascular), Facility of Use - Global Forecast to 2031
The pharmaceutical drug delivery market is projected to grow from USD 2,152.45 billion in 2026 to USD 2,922.82 billion by 2031, at a CAGR of 6.3% during the forecast period. The market is growing at a healthy pace due to an increase in chronic diseases globally and the use of biologics, biosimilars, and advanced therapies. The shift towards patient-friendly and self-administration therapies is facilitating the adoption of new injectable, inhalation, transdermal, and targeted delivery systems in the developed and emerging economies. The trend of prescribing large-molecule drugs has led to a rise in investments in cutting-edge delivery vehicles such as lipid nanoparticles, long-acting depots, controlled-release formulations, and wearable injectors. Meanwhile, digital and connected drug-device technologies are facilitating greater treatment precision, patient adherence, and remote monitoring of patients. Market growth is enabled by innovations in device engineering, automation, and biologic stabilization. Nevertheless, the industry is still grappling with issues such as high costs of developing and manufacturing products, more stringent global regulatory requirements, and complexities related to the supply chain and sterility. However, continuous innovation and a significant move towards home-based and patient-centric care are still fueling strong growth in the global pharmaceutical drug delivery market.
“Injectable drug delivery segment accounted for the largest market share in 2025”
Based on route of administration, the injectable drug delivery segment dominates the pharmaceutical drug delivery market at a global level. This is linked to the growing incidence of chronic diseases both in developed and developing countries, as well as the worldwide trend of using biologics, biosimilars, peptides, oligonucleotides, and cell & gene therapies that are only parenterally administered due to low oral bioavailability and degradation issues. Moreover, innovations in prefilled syringes, autoinjectors, wearable injectors, needles, free jet injectors, subcutaneous rapid infusion systems, and micro/nanocarrier platforms have changed the injectable drug delivery landscape completely by making drug delivery safer, more comfortable, and easier to use. These technological advances have led to a huge increase in self-administration out of the hospital and have pushed the penetration of injectable drug delivery systems in the global market much quicker.
“Hospitals segment captured the largest share of the market for formulations in 2025”
The hospital segment accounted for the largest share of the global pharmaceutical drug delivery market in 2025. Hospitals are supported by advanced infrastructure, trained clinical staff, and have the capability to manage biologics, monoclonal antibodies, radiopharmaceuticals, and other specialty treatments that require precise dosing and continuous monitoring. They offer the perfect setting for such treatments. An increased usage of large-molecule drugs has contributed to a rise in demand for sophisticated hospital-based delivery systems such as infusion pumps, long-acting injectables, nanoparticle formulations, and depot implants. Such innovative drug delivery devices and methods assist in keeping the drugs stable, ensure accurate administration, and thereby, significantly enhance the effectiveness of therapies. Worldwide regulatory bodies keep safety, device, drug compatibility, and human factor performance at the top of their priorities when it comes to hospital-administered delivery platforms. Therefore, to meet the regulations, the companies have to reinforce design, testing, and quality controls. Hospitals continue to be the most important Facility of Use in the global drug delivery landscape, as they handle more and more cases that need advanced parenteral and device-assisted therapies.
“In 2025, North America dominated the pharmaceutical drug delivery market”
North America held the largest market share in 2025, which can be attributed to an advanced healthcare infrastructure, strong uptake of biologics and specialty medicines, and extensive R&D activity. Autoinjectors, prefilled syringes, wearable injectors, and connected drug, device platforms are adopted as a result of high chronic disease prevalence and a growing demand for self-administration in the region. The area is home to major pharmaceutical and drug, device companies that are constantly looking for new formulation technologies, high-precision injection systems, nanoparticle-based platforms, and controlled-release mechanisms. The regulatory pathways, especially the US FDA’s ones, are very supportive, and thus, combination products and biologic delivery systems help to maintain North America’s dominant position. Besides that, strong biotech clusters, research institutions, and CDMOs are also helping to create a highly innovative drug delivery ecosystem.
Breakdown of supply-side primary interviews:
Research Coverage
This report studies the pharmaceutical drug delivery market based on route of administration, application, facility of use, and region. The report also studies factors (drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies for strengthening their market presence.
This report provides insights into the following pointers:
“Injectable drug delivery segment accounted for the largest market share in 2025”
Based on route of administration, the injectable drug delivery segment dominates the pharmaceutical drug delivery market at a global level. This is linked to the growing incidence of chronic diseases both in developed and developing countries, as well as the worldwide trend of using biologics, biosimilars, peptides, oligonucleotides, and cell & gene therapies that are only parenterally administered due to low oral bioavailability and degradation issues. Moreover, innovations in prefilled syringes, autoinjectors, wearable injectors, needles, free jet injectors, subcutaneous rapid infusion systems, and micro/nanocarrier platforms have changed the injectable drug delivery landscape completely by making drug delivery safer, more comfortable, and easier to use. These technological advances have led to a huge increase in self-administration out of the hospital and have pushed the penetration of injectable drug delivery systems in the global market much quicker.
“Hospitals segment captured the largest share of the market for formulations in 2025”
The hospital segment accounted for the largest share of the global pharmaceutical drug delivery market in 2025. Hospitals are supported by advanced infrastructure, trained clinical staff, and have the capability to manage biologics, monoclonal antibodies, radiopharmaceuticals, and other specialty treatments that require precise dosing and continuous monitoring. They offer the perfect setting for such treatments. An increased usage of large-molecule drugs has contributed to a rise in demand for sophisticated hospital-based delivery systems such as infusion pumps, long-acting injectables, nanoparticle formulations, and depot implants. Such innovative drug delivery devices and methods assist in keeping the drugs stable, ensure accurate administration, and thereby, significantly enhance the effectiveness of therapies. Worldwide regulatory bodies keep safety, device, drug compatibility, and human factor performance at the top of their priorities when it comes to hospital-administered delivery platforms. Therefore, to meet the regulations, the companies have to reinforce design, testing, and quality controls. Hospitals continue to be the most important Facility of Use in the global drug delivery landscape, as they handle more and more cases that need advanced parenteral and device-assisted therapies.
“In 2025, North America dominated the pharmaceutical drug delivery market”
North America held the largest market share in 2025, which can be attributed to an advanced healthcare infrastructure, strong uptake of biologics and specialty medicines, and extensive R&D activity. Autoinjectors, prefilled syringes, wearable injectors, and connected drug, device platforms are adopted as a result of high chronic disease prevalence and a growing demand for self-administration in the region. The area is home to major pharmaceutical and drug, device companies that are constantly looking for new formulation technologies, high-precision injection systems, nanoparticle-based platforms, and controlled-release mechanisms. The regulatory pathways, especially the US FDA’s ones, are very supportive, and thus, combination products and biologic delivery systems help to maintain North America’s dominant position. Besides that, strong biotech clusters, research institutions, and CDMOs are also helping to create a highly innovative drug delivery ecosystem.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%)
- By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)
- By End User:
- By Designation:
- By Region:
Research Coverage
This report studies the pharmaceutical drug delivery market based on route of administration, application, facility of use, and region. The report also studies factors (drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies for strengthening their market presence.
This report provides insights into the following pointers:
- Analysis of Key Drivers, Restraints, Opportunities, Challenges
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pharmaceutical drug delivery market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the pharmaceutical drug delivery market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pharmaceutical drug delivery market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 MAJOR STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN PHARMACEUTICAL DRUG DELIVERY MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW
3.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION & COUNTRY (2025)
3.3 PHARMACEUTICAL DRUG DELIVERY MARKET: REGIONAL MIX
3.4 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Advancements in drug delivery technologies
4.2.1.2 Rising burden of chronic diseases and aging population
4.2.1.3 Growing adoption of biologics and biosimilars
4.2.1.4 Growing emphasis on patient convenience
4.2.1.5 Increasing investments in pharmaceutical R&D
4.2.2 RESTRAINTS
4.2.2.1 Infections associated with needlestick injuries
4.2.2.2 Stringent government regulations
4.2.3 OPPORTUNITIES
4.2.3.1 Geographic expansion into emerging markets
4.2.3.2 Integration with digital health & remote monitoring
4.2.4 CHALLENGES
4.2.4.1 Pricing pressure by governing bodies
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL DRUG DELIVERY INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025
5.5.1.1 Average selling price trend of injectable drug delivery products, by key player, 2023?2025
5.5.1.2 Average selling price trend of oral drug delivery products, by key player, 2023?2025
5.5.1.3 Average selling price trend of topical drug delivery products, by key player, 2023?2025
5.5.2 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023–2025
5.5.2.1 Average selling price trend of injectable drug delivery products, by region, 2023?2025
5.5.2.2 Average selling price trend of oral drug delivery products, by region, 2023?2025
5.5.2.3 Average selling price trend of topical drug delivery products, by region, 2023?2025
5.5.2.4 Average selling price trend of pulmonary drug delivery products, by region, 2023?2025
5.5.2.5 Average selling price trend of ocular drug delivery products, by region, 2023?2025
5.5.2.6 Average selling price trend of nasal drug delivery products, by region, 2023?2025
5.6 TRADE ANALYSIS
5.6.1 TRADE DATA FOR HS CODE 3004
5.6.1.1 Import data for HS Code 3004
5.6.1.2 Export data for HS Code 3004
5.6.2 TRADE DATA FOR HS CODE 9018
5.6.2.1 Import data for HS Code 9018
5.6.2.2 Export data for HS Code 9018
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING SCENARIO
5.10 REIMBURSEMENT ANALYSIS
5.11 PIPELINE ANALYSIS
5.12 SUCCESS STORIES & REAL-WORLD APPLICATIONS
5.12.1 MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM
5.12.2 YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY
5.12.3 ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE
5.13 IMPACT OF US TARIFFS—PHARMACEUTICAL DRUG DELIVERY MARKET
5.13.1 INTRODUCTION
5.13.2 KEY TARIFF RATES
5.13.3 PRICE IMPACT ANALYSIS
5.13.4 IMPACT ON COUNTRIES/REGIONS
5.13.5 IMPACT ON END-USE INDUSTRIES
5.13.5.1 Impact on end-use industries: formulations
5.13.5.1.1 Hospitals
5.13.5.1.2 Ambulatory surgical centers/clinics
5.13.5.1.3 Home care settings
5.13.5.2 Impact on end-use industries: devices
5.13.5.2.1 Pharmaceutical companies
5.13.5.2.2 Biotechnology companies
5.13.5.2.3 Contract development and manufacturing organizations (CDMOs) & contract research organizations (CROs)
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Nanotechnology-based drug delivery
6.1.1.2 Smart/connected drug delivery devices
6.1.1.3 Needle-free injection systems and microneedle patches
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 3D printed & personalized drug delivery
6.1.2.2 AI/ML in drug delivery & formulation
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Smart monitoring, IoT, and data-driven control
6.1.3.2 Cell & gene delivery vectors
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.2.1 NEAR-TERM (2025–2027)
6.2.2 MID-TERM (2028–2030)
6.2.3 LONG-TERM (2030+)
6.3 PATENT ANALYSIS
6.3.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY MARKET
6.3.2 JURISDICTION & TOP APPLICANT ANALYSIS
6.4 FUTURE APPLICATIONS
6.4.1 PATIENT-CENTRIC DRUG DELIVERY SYSTEMS
6.4.2 MINIMALLY INVASIVE AND SELF-ADMINISTERED DELIVERY
6.4.3 LONG-ACTING AND BIOLOGIC DRUG DELIVERY SYSTEMS
6.4.4 DIGITAL AND AI-ENABLED DRUG DELIVERY
6.5 IMPACT OF AI/GENERATIVE AI ON PHARMACEUTICAL DRUG DELIVERY MARKET
6.5.1 INTRODUCTION
6.5.2 MARKET POTENTIAL IN PHARMACEUTICAL DRUG DELIVERY ECOSYSTEM
6.5.3 AI USE CASES
6.5.4 KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL DRUG DELIVERY MARKET
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENERGY-EFFICIENT MANUFACTURING & CARBON REDUCTION IN PHARMACEUTICAL DRUG DELIVERY
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS (DEVICES)
8.1.2 KEY STAKEHOLDERS IN BUYING PROCESS (FORMULATIONS)
8.1.3 BUYING CRITERIA
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1 DECISION-MAKING PROCESS
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4 MARKET PROFITABILITY
9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION
9.1 INTRODUCTION
9.2 INJECTABLE DRUG DELIVERY
9.2.1 DEVICES
9.2.1.1 Conventional injection devices
9.2.1.1.1 Rising incidence of chronic diseases and low cost of manufacturing to drive the market
9.2.1.1.2 Global Volume Analysis of Conventional Injection Devices, 2024-2031(Ten Thousand Units)
9.2.1.1.3 By material
9.2.1.1.3.1 Glass
9.2.1.1.3.2 Plastic
9.2.1.1.4 By usability
9.2.1.1.4.1 Reusable
9.2.1.1.4.2 Disposable
9.2.1.1.5 By type
9.2.1.1.5.1 Fillable syringes
9.2.1.1.6 Prefilled syringes
9.2.1.2 Self-injection devices
9.2.1.2.1 Global Volume Analysis of Self-Injection Devices, 2024-2031(Ten Thousand Units)
9.2.1.2.2 Needle-free injectors
9.2.1.2.3 Autoinjectors
9.2.1.2.4 Pen injectors
9.2.1.2.5 Wearable injectors
9.2.1.3 Other injectable devices
9.3 FORMULATIONS
9.3.1 BY TYPE
9.3.1.1 Conventional drug delivery formulations
9.3.1.2 Novel drug delivery formulations
9.3.1.3 long-acting injectable formulations
9.3.2 BY FORMULATION PACKAGING
9.3.2.1 Ampoules
9.3.2.1.1 Helps maintain the stability of drugs, thereby enhancing efficacy
9.3.2.2 Vials
9.3.2.2.1 Ability to store drug formulations for extensive periods
9.3.2.3 Cartridges
9.3.2.3.1 Offers higher dose accuracy and patient convenience
9.3.2.4 Bottles
9.3.2.4.1 Easy storage of solutions and emulsions drives demand
9.4 ORAL DRUG DELIVERY
9.4.1 SOLID ORAL DRUGS
9.4.1.1 Tablets
9.4.1.1.1 Development of mini-tablets is a key trend in this market segment
9.4.1.2 Capsules
9.4.1.2.1 Easy absorption of drugs and decreased irritation in GI tract drive use of capsules
9.4.1.3 Powders
9.4.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms
9.4.1.4 Granules
9.4.1.4.1 Increasing adoption of modified-release and pediatric-friendly formulations driving granules market growth
9.4.1.5 Lozenges
9.4.1.5.1 Prolonged drug release and localized action enhancing adoption of lozenges
9.4.2 LIQUID ORAL DRUGS
9.4.2.1 Syrups
9.4.2.1.1 Easy administration to patients with swallowing difficulties
9.4.2.2 Solutions
9.4.2.2.1 Geriatric and pediatric patients generally prefer solutions
9.4.2.3 Emulsions
9.4.2.3.1 Emulsions offer enhanced solubility and stability with ease of administration
9.4.2.4 Suspensions
9.4.2.4.1 Increasing demand for pediatric and geriatric-friendly formulations is driving the oral suspension market growth
9.4.2.5 Elixirs
9.4.2.5.1 Elixirs are a preferred choice for the pediatric population
9.4.3 SEMI-SOLID ORAL DRUGS
9.4.3.1 Gels
9.4.3.1.1 Gels are used for controlled drug release
9.4.3.2 Pastes
9.4.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis
9.5 TOPICAL DRUG DELIVERY
9.5.1 SEMI-SOLID FORMULATIONS
9.5.1.1 Ointments
9.5.1.1.1 Ointments are widely used in analgesic indications
9.5.1.2 Creams
9.5.1.2.1 Creams are either water-in-oil or oil-in-water emulsions
9.5.1.3 Lotions
9.5.1.3.1 Easy administration of lotions to drive demand among end users
9.5.1.4 Gels
9.5.1.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels
9.5.1.5 Pastes
9.5.1.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation
9.5.2 LIQUID FORMULATIONS
9.5.2.1 Suspensions
9.5.2.1.1 Higher rate of bioavailability and controlled onset of action to drive market
9.5.2.2 Emulsions
9.5.2.2.1 Improved spreadability, stability, and controlled release of active ingredients
9.5.2.3 Solutions
9.5.2.3.1 Uniform & rapid drug delivery to boost demand
9.5.3 SOLID FORMULATIONS
9.5.3.1 Powders
9.5.3.1.1 Powders have a very fine particle size that covers a large surface area per unit weight
9.5.3.2 Suppositories
9.5.3.2.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug
9.5.4 FILMS
9.5.4.1 Next-generation advancements to boost demand
9.5.5 TRANSDERMAL FORMULATIONS
9.5.5.1 Transdermal patches
9.5.5.1.1 Transdermal patches prevent premature metabolization of drugs through the liver
9.5.6 TRANSDERMAL GELS
9.5.6.1 Rapid release of drugs to fuel uptake
9.5.7 TRANSDERMAL SPRAYS
9.5.7.1 Targeted approach to boost demand
9.6 OCULAR DRUG DELIVERY
9.6.1 LIQUID FORMULATIONS
9.6.1.1 Eye drops
9.6.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth
9.6.1.2 Liquid sprays
9.6.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops
9.6.2 SEMI-SOLID FORMULATIONS
9.6.2.1 Gels
9.6.2.1.1 High viscosity of drugs, prolonged drug release, and ease of drug administration contribute to market growth
9.6.2.2 Eye ointments
9.6.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug
9.6.3 OCULAR DEVICES
9.6.3.1 Drug-coated contact lenses
9.6.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses
9.6.3.2 Ocular inserts
9.6.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye
9.7 PULMONARY DRUG DELIVERY
9.7.1 PULMONARY DRUG DELIVERY DEVICE
9.7.1.1 Metered-dose Inhalers
9.7.1.2 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath
9.7.1.2.1 Global Volume Analysis of Metered Dose Inhalers, By Region, 2024–2031 (Ten thousand units)
9.7.1.3 Dry Powder Inhalers
9.7.1.3.1 Dry powder inhaler formulations are chemically more stable than their counterparts
9.7.1.3.2 Global Volume Analysis of Dry Powder Inhalers, By Region, 2024–2031 (Ten thousand units)
9.7.1.4 Nebulizers
9.7.1.4.1 Global Volume Analysis of Nebulizers, By Region, 2024–2031 (Ten thousand units)
9.7.1.4.2 Jet nebulizers
9.7.1.4.2.1 Jet nebulizers account for the largest share of the nebulizers market
9.7.1.4.3 Ultrasonic nebulizers
9.7.1.4.3.1 Ultrasonic nebulizers are easy to use and comfortable to handle
9.7.1.4.4 Soft mist nebulizers
9.7.1.4.4.1 Soft mist nebulizers are preferred for the treatment of severe COPD
9.7.2 PULMONARY DRUG DELIVERY FORMULATION
9.7.2.1 Suspension Aerosol
9.7.2.2 Suspension Aerosols Enable Delivery of Insoluble Drug Formulations
9.7.2.3 Solution Aerosol
9.7.2.3.1 Solution Aerosols Support Uniform Drug Distribution and Formulation Flexibility
9.7.3 DRY POWDER FORMULATIONS
9.8 NASAL DRUG DELIVERY
9.8.1 NASAL DROPS & LIQUIDS
9.8.1.1 Nasal drops are considered more efficient than nasal sprays
9.8.2 NASAL SPRAYS
9.8.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing
9.8.3 NASAL POWDERS
9.8.3.1 Absence of preservatives and superior stability of formulations are some advantages associated with nasal powders
9.9 TRANSMUCOSAL DRUG DELIVERY
9.9.1 ORAL FORMULATIONS
9.9.1.1 Buccal drug delivery
9.9.1.1.1 Buccal drug delivery system is suitable for local and systemic therapies
9.9.1.2 Sublingual drug delivery
9.9.1.2.1 Higher rate of drug absorption compared to oral route drives adoption
9.9.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES
9.9.2.1 Rectal transmucosal drug delivery
9.9.2.1.1 Enhanced bioavailability and bypassing first-pass metabolism
9.9.2.2 Vaginal transmucosal drug delivery
9.9.2.2.1 Higher permeability and direct access to target systems drive adoption
9.10 IMPLANTABLE DRUG DELIVERY
9.10.1 ACTIVE IMPLANTABLE DRUG DELIVERY
9.10.1.1 Active implantable devices are used for diagnostic monitoring, body fluid transportation, and ionizing radiation
9.10.2 PASSIVE IMPLANTABLE DRUG DELIVERY
9.10.2.1 Passive implantable drug delivery systems offer a means to achieve targeted drug delivery
9.11 OTIC DRUG DELIVERY
9.11.1 EAR DROPS
9.11.1.1 Increasing prevalence of ear infections and demand for localized treatment are driving ear drops segment growth
9.11.2 OTIC SPRAYS
9.11.2.1 Growing demand for uniform drug distribution and improved patient convenience driving adoption
10 PHARMACEUTICAL DRUG DELIVERY, BY APPLICATION
10.1 INTRODUCTION
10.2 INJECTABLE DRUG DELIVERY
10.2.1 METABOLIC DISORDERS (DIABETES, OBESITY)
10.2.1.1 Rising burden of diabetes and obesity driving strong adoption of injectable drug delivery
10.2.2 CANCER
10.2.2.1 Rising prevalence of cancer and growing availability of therapeutics to drive market
10.2.3 IMMUNOLOGICAL & AUTOIMMUNE DISEASES
10.2.3.1 Increased focus on early-stage diagnosis and treatment to propel segment growth
10.2.4 INFECTIOUS DISEASES
10.2.4.1 Increasing use of liposomes to aid segment growth
10.2.5 OTHER INJECTABLE DRUG DELIVERY APPLICATIONS
10.3 ORAL DRUG DELIVERY
10.3.1 CARDIOVASCULAR DISEASES
10.3.1.1 High prevalence of CVDs and widespread use of oral therapies drive market
10.3.2 METABOLIC DISORDERS (DIABETES, OBESITY)
10.3.2.1 Growing preference for self-injection devices over traditional syringes to augment market growth
10.3.3 CNS DISORDERS
10.3.3.1 Chronic nature of CNS disorders and long-term therapy needs driving oral drug delivery adoption
10.3.4 INFECTIOUS DISEASES
10.3.4.1 High global infection burden and outpatient treatment trends driving oral drug delivery adoption
10.3.5 ONCOLOGY (ORAL THERAPIES)
10.3.5.1 Shift toward targeted therapies and at-home treatment driving oral drug delivery in oncology
10.3.6 OTHER ORAL DRUG DELIVERY APPLICATIONS
10.4 TOPICAL DRUG DELIVERY
10.4.1 DERMATOLOGICAL DISORDERS
10.4.1.1 High prevalence of skin disorders driving strong demand for topical drug delivery
10.4.2 PAIN MANAGEMENT
10.4.2.1 Localized relief and reduced systemic side-effects driving topical drug delivery in pain management
10.4.3 WOUND CARE
10.4.3.1 Rising incidence of chronic wounds and surgical procedures driving topical drug delivery in wound care
10.5 OCULAR DRUG DELIVERY
10.5.1 RETINAL DISORDERS
10.5.1.1 Rising prevalence of retinal diseases and biologics adoption driving growth in the retinal disorders segment
10.5.2 GLAUCOMA
10.5.2.1 High prevalence and lifelong therapy requirements driving ocular drug delivery in glaucoma
10.5.3 EYE INFECTIOUS DISEASES
10.5.3.1 High incidence of ocular infections and need for rapid localized therapy driving eye infectious diseases segment
10.5.4 OTHER OCULAR DRUG DELIVERY APPLICATIONS
10.6 PULMONARY DRUG DELIVERY
10.6.1 ASTHMA
10.6.1.1 High global asthma prevalence and lifelong inhalation therapy driving pulmonary drug delivery demand
10.6.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
10.6.2.1 Chronic disease burden and high reliance on inhalation therapies driving pulmonary drug delivery in COPD
10.6.3 PULMONARY INFECTIONS
10.6.3.1 High burden of respiratory infections and need for rapid drug action driving pulmonary drug delivery in pulmonary infections
10.6.4 OTHER PULMONARY DRUG DELIVERY APPLICATIONS
10.7 NASAL DRUG DELIVERY
10.7.1 ALLERGIC RHINITIS
10.7.1.1 High prevalence of allergic conditions driving nasal drug delivery in allergic rhinitis
10.7.2 SINUSITIS
10.7.2.1 High prevalence of sinus infections and need for targeted therapy driving nasal drug delivery in sinusitis
10.7.3 OTHER NASAL DRUG DELIVERY APPLICATIONS
10.8 TRANSMUCOSAL DRUG DELIVERY
10.8.1 PAIN MANAGEMENT
10.8.1.1 Rapid onset and improved patient compliance driving transmucosal drug delivery in pain management
10.8.2 HORMONE THERAPY
10.8.2.1 Need for controlled hormone delivery and long-term therapy driving transmucosal drug delivery in hormonal therapy
10.8.3 INFECTIOUS DISEASES
10.8.3.1 Targeted local therapy and improved patient compliance driving transmucosal drug delivery in infectious diseases
10.8.4 OTHER TRANSMUCOSAL DRUG DELIVERY APPLICATIONS
10.9 IMPLANTABLE DRUG DELIVERY
10.9.1 HORMONAL THERAPY/CONTRACEPTION
10.9.1.1 Long-acting reversible contraceptives and sustained hormone delivery driving market
10.9.2 CANCER
10.9.2.1 Targeted therapy and sustained drug release driving implantable drug delivery in cancer
10.9.3 OTHER IMPLANTABLE DRUG DELIVERY APPLICATIONS
10.10 OTIC DRUG DELIVERY
10.10.1 EAR INFECTIONS
10.10.1.1 High incidence of otitis and pediatric burden driving otic drug delivery in ear infections
10.10.2 CERUMEN REMOVAL
10.10.2.1 Growing demand for ear hygiene and non-invasive treatments driving otic drug delivery in cerumen removal
10.10.3 OTHER OTIC DRUG DELIVERY APPLICATIONS
11 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE
11.1 INTRODUCTION
11.2 FORMULATIONS, BY FACILITY OF USE
11.2.1 HOSPITALS
11.2.1.1 Increased hospital demand for complex drug delivery boosts market uptake
11.2.2 HOME CARE SETTINGS
11.2.2.1 Rising preference for self-administration of medicine to drive market
11.2.3 AMBULATORY SURGERY CENTERS/CLINICS
11.2.3.1 Shift toward cost-effective outpatient care driving adoption of drug delivery systems
11.2.4 DIAGNOSTIC CENTERS
11.2.4.1 Rising prevalence of chronic diseases to support market growth
11.2.5 LONG-TERM CARE SETTINGS
11.2.5.1 Growing elderly population and chronic disease burden to drive market
11.2.6 OTHER FACILITIES OF USE
11.3 DEVICES, BY FACILITY OF USE
11.3.1 PHARMACEUTICAL COMPANIES
11.3.1.1 Increasing focus on advanced drug delivery systems driving market growth
11.3.2 BIOTECHNOLOGY COMPANIES
11.3.2.1 Enabling complex biologics delivery and decentralized care
11.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS)
11.3.3.1 Fueling innovation through cost-effective and scalable manufacturing solutions
12 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
12.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031
12.2.3 US
12.2.3.1 US to dominate North American pharmaceutical drug delivery market
12.2.4 CANADA
12.2.4.1 Government support for research and the prevalence of chronic diseases to drive the market in Canada
12.3 EUROPE
12.3.1 EUROPE: MACROECONOMIC OUTLOOK
12.3.2 EUROPE: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031
12.3.3 GERMANY
12.3.3.1 Growing focus of pharmaceutical companies on the development of various drug delivery products to drive market
12.3.4 UK
12.3.4.1 NHS support and growing access to cost-effective pen needles to drive the market
12.3.5 FRANCE
12.3.5.1 Presence of leading pharmaceutical companies, along with the increasing prevalence of chronic diseases, to drive market growth in France
12.3.6 ITALY
12.3.6.1 Increasing focus on clinical research and growing popularity of branded drugs to drive demand for pharmaceutical drug manufacturing
12.3.7 DENMARK
12.3.7.1 Strong R&D ecosystem, biologics innovation, and export-driven pharmaceutical manufacturing to drive demand for pharmaceutical drug delivery
12.3.8 SWEDEN
12.3.8.1 Strong life sciences ecosystem, biologics innovation, and government-backed healthcare system to drive demand for pharmaceutical drug delivery
12.3.9 SPAIN
12.3.9.1 Increase in biologics production to support market growth
12.3.10 NETHERLANDS
12.3.10.1 Enhancing patient care through innovation and collaboration to drive market growth
12.3.11 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031
12.4.3 CHINA
12.4.3.1 A high diabetic population and rising prevalence of chronic diseases contribute to China’s large demand
12.4.4 JAPAN
12.4.4.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan
12.4.5 INDIA
12.4.5.1 Growing generic demand and rising government initiatives to drive market
12.4.6 AUSTRALIA
12.4.6.1 Rising investment and a favorable tax environment to support growth
12.4.7 SOUTH KOREA
12.4.7.1 Strong government support and investments in healthcare & biopharmaceuticals to propel growth
12.4.8 NEW ZEALAND
12.4.8.1 Strong public healthcare system, rising biologics adoption, and focus on advanced therapies to drive demand
12.4.9 THAILAND
12.4.9.1 Regulatory reforms and healthcare initiatives to fuel market growth
12.4.10 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
12.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
12.5.3 LATIN AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031
12.5.4 BRAZIL
12.5.4.1 Brazil attracting multinational pharmaceutical companies
12.5.5 MEXICO
12.5.5.1 Growth and diversification in Mexico's pharmaceutical exports
12.5.6 ARGENTINA
12.5.6.1 Expanding domestic pharmaceutical production, increasing chronic disease burden, and growing biologics adoption to drive demand
12.5.7 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
12.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024–2031
12.6.3 GCC COUNTRIES
12.6.3.1 Kingdom of Saudi Arabia (KSA)
12.6.3.1.1 Healthcare reforms and global partnerships fuel pharmaceutical market growth
12.6.3.2 United Arab Emirates (UAE)
12.6.3.2.1 Government supports and growing local manufacturing to drive market growth
12.6.3.3 Rest of GCC Countries
12.6.4 REST OF MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3 REVENUE ANALYSIS, 2023–2025
13.3.1 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS
13.3.2 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS
13.4 MARKET SHARE ANALYSIS, 2025
13.4.1 GLOBAL INJECTABLE DRUG DELIVERY MANUFACTURERS
13.4.1.1 Global Injectable Drug Delivery Device Manufacturers
13.4.1.2 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
13.4.1.2.1 US Injectable Drug Delivery Formulation Manufacturers
13.4.1.3 Europe Injectable drug delivery formulation manufacturers
13.4.2 GLOBAL ORAL DRUG DELIVERY MANUFACTURERS
13.4.2.1 US oral drug delivery formulation manufacturers
13.4.2.2 Europe oral drug delivery manufacturers
13.4.3 GLOBAL TOPICAL DRUG DELIVERY MANUFACTURERS
13.4.3.1 US Topical Drug Delivery Formulation Manufacturers
13.4.3.2 Europe Topical Drug Delivery Manufacturers
13.5 BRAND/PRODUCT COMPARISON
13.6 R&D EXPENDITURE OF KEY PLAYERS
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.7.1 COMPANY VALUATION
13.7.2 FINANCIAL METRICS
13.8 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025
13.8.1 STARS
13.8.2 EMERGING LEADERS
13.8.3 PERVASIVE PLAYERS
13.8.4 PARTICIPANTS
13.8.5 COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025
13.8.5.1 Company footprint
13.8.5.2 Region footprint
13.8.5.3 Product type footprint
13.8.5.4 Usability footprint
13.9 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025
13.9.1 STARS
13.9.2 EMERGING LEADERS
13.9.3 PERVASIVE PLAYERS
13.9.4 PARTICIPANTS
13.9.5 COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025
13.9.5.1 Company footprint
13.9.5.2 Region footprint
13.9.5.3 Route of administration footprint
13.9.5.4 Therapeutic application footprint
13.10 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025
13.10.1 PROGRESSIVE COMPANIES
13.10.2 DYNAMIC COMPANIES
13.10.3 STARTING BLOCKS
13.10.4 RESPONSIVE COMPANIES
13.10.5 COMPETITIVE BENCHMARKING: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025
13.10.5.1 Detailed list of key startups/SMEs
13.10.5.2 Competitive benchmarking of startups/SMEs
13.11 COMPETITIVE SCENARIO
13.11.1 PRODUCT APPROVALS AND LAUNCHES
13.11.2 DEALS
13.11.3 EXPANSIONS
13.11.4 OTHER DEVELOPMENTS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 MAJOR STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN PHARMACEUTICAL DRUG DELIVERY MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW
3.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION & COUNTRY (2025)
3.3 PHARMACEUTICAL DRUG DELIVERY MARKET: REGIONAL MIX
3.4 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Advancements in drug delivery technologies
4.2.1.2 Rising burden of chronic diseases and aging population
4.2.1.3 Growing adoption of biologics and biosimilars
4.2.1.4 Growing emphasis on patient convenience
4.2.1.5 Increasing investments in pharmaceutical R&D
4.2.2 RESTRAINTS
4.2.2.1 Infections associated with needlestick injuries
4.2.2.2 Stringent government regulations
4.2.3 OPPORTUNITIES
4.2.3.1 Geographic expansion into emerging markets
4.2.3.2 Integration with digital health & remote monitoring
4.2.4 CHALLENGES
4.2.4.1 Pricing pressure by governing bodies
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL DRUG DELIVERY INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025
5.5.1.1 Average selling price trend of injectable drug delivery products, by key player, 2023?2025
5.5.1.2 Average selling price trend of oral drug delivery products, by key player, 2023?2025
5.5.1.3 Average selling price trend of topical drug delivery products, by key player, 2023?2025
5.5.2 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023–2025
5.5.2.1 Average selling price trend of injectable drug delivery products, by region, 2023?2025
5.5.2.2 Average selling price trend of oral drug delivery products, by region, 2023?2025
5.5.2.3 Average selling price trend of topical drug delivery products, by region, 2023?2025
5.5.2.4 Average selling price trend of pulmonary drug delivery products, by region, 2023?2025
5.5.2.5 Average selling price trend of ocular drug delivery products, by region, 2023?2025
5.5.2.6 Average selling price trend of nasal drug delivery products, by region, 2023?2025
5.6 TRADE ANALYSIS
5.6.1 TRADE DATA FOR HS CODE 3004
5.6.1.1 Import data for HS Code 3004
5.6.1.2 Export data for HS Code 3004
5.6.2 TRADE DATA FOR HS CODE 9018
5.6.2.1 Import data for HS Code 9018
5.6.2.2 Export data for HS Code 9018
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 INVESTMENT & FUNDING SCENARIO
5.10 REIMBURSEMENT ANALYSIS
5.11 PIPELINE ANALYSIS
5.12 SUCCESS STORIES & REAL-WORLD APPLICATIONS
5.12.1 MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM
5.12.2 YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY
5.12.3 ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE
5.13 IMPACT OF US TARIFFS—PHARMACEUTICAL DRUG DELIVERY MARKET
5.13.1 INTRODUCTION
5.13.2 KEY TARIFF RATES
5.13.3 PRICE IMPACT ANALYSIS
5.13.4 IMPACT ON COUNTRIES/REGIONS
5.13.5 IMPACT ON END-USE INDUSTRIES
5.13.5.1 Impact on end-use industries: formulations
5.13.5.1.1 Hospitals
5.13.5.1.2 Ambulatory surgical centers/clinics
5.13.5.1.3 Home care settings
5.13.5.2 Impact on end-use industries: devices
5.13.5.2.1 Pharmaceutical companies
5.13.5.2.2 Biotechnology companies
5.13.5.2.3 Contract development and manufacturing organizations (CDMOs) & contract research organizations (CROs)
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Nanotechnology-based drug delivery
6.1.1.2 Smart/connected drug delivery devices
6.1.1.3 Needle-free injection systems and microneedle patches
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 3D printed & personalized drug delivery
6.1.2.2 AI/ML in drug delivery & formulation
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Smart monitoring, IoT, and data-driven control
6.1.3.2 Cell & gene delivery vectors
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.2.1 NEAR-TERM (2025–2027)
6.2.2 MID-TERM (2028–2030)
6.2.3 LONG-TERM (2030+)
6.3 PATENT ANALYSIS
6.3.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY MARKET
6.3.2 JURISDICTION & TOP APPLICANT ANALYSIS
6.4 FUTURE APPLICATIONS
6.4.1 PATIENT-CENTRIC DRUG DELIVERY SYSTEMS
6.4.2 MINIMALLY INVASIVE AND SELF-ADMINISTERED DELIVERY
6.4.3 LONG-ACTING AND BIOLOGIC DRUG DELIVERY SYSTEMS
6.4.4 DIGITAL AND AI-ENABLED DRUG DELIVERY
6.5 IMPACT OF AI/GENERATIVE AI ON PHARMACEUTICAL DRUG DELIVERY MARKET
6.5.1 INTRODUCTION
6.5.2 MARKET POTENTIAL IN PHARMACEUTICAL DRUG DELIVERY ECOSYSTEM
6.5.3 AI USE CASES
6.5.4 KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL DRUG DELIVERY MARKET
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENERGY-EFFICIENT MANUFACTURING & CARBON REDUCTION IN PHARMACEUTICAL DRUG DELIVERY
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS (DEVICES)
8.1.2 KEY STAKEHOLDERS IN BUYING PROCESS (FORMULATIONS)
8.1.3 BUYING CRITERIA
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1 DECISION-MAKING PROCESS
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4 MARKET PROFITABILITY
9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION
9.1 INTRODUCTION
9.2 INJECTABLE DRUG DELIVERY
9.2.1 DEVICES
9.2.1.1 Conventional injection devices
9.2.1.1.1 Rising incidence of chronic diseases and low cost of manufacturing to drive the market
9.2.1.1.2 Global Volume Analysis of Conventional Injection Devices, 2024-2031(Ten Thousand Units)
9.2.1.1.3 By material
9.2.1.1.3.1 Glass
9.2.1.1.3.2 Plastic
9.2.1.1.4 By usability
9.2.1.1.4.1 Reusable
9.2.1.1.4.2 Disposable
9.2.1.1.5 By type
9.2.1.1.5.1 Fillable syringes
9.2.1.1.6 Prefilled syringes
9.2.1.2 Self-injection devices
9.2.1.2.1 Global Volume Analysis of Self-Injection Devices, 2024-2031(Ten Thousand Units)
9.2.1.2.2 Needle-free injectors
9.2.1.2.3 Autoinjectors
9.2.1.2.4 Pen injectors
9.2.1.2.5 Wearable injectors
9.2.1.3 Other injectable devices
9.3 FORMULATIONS
9.3.1 BY TYPE
9.3.1.1 Conventional drug delivery formulations
9.3.1.2 Novel drug delivery formulations
9.3.1.3 long-acting injectable formulations
9.3.2 BY FORMULATION PACKAGING
9.3.2.1 Ampoules
9.3.2.1.1 Helps maintain the stability of drugs, thereby enhancing efficacy
9.3.2.2 Vials
9.3.2.2.1 Ability to store drug formulations for extensive periods
9.3.2.3 Cartridges
9.3.2.3.1 Offers higher dose accuracy and patient convenience
9.3.2.4 Bottles
9.3.2.4.1 Easy storage of solutions and emulsions drives demand
9.4 ORAL DRUG DELIVERY
9.4.1 SOLID ORAL DRUGS
9.4.1.1 Tablets
9.4.1.1.1 Development of mini-tablets is a key trend in this market segment
9.4.1.2 Capsules
9.4.1.2.1 Easy absorption of drugs and decreased irritation in GI tract drive use of capsules
9.4.1.3 Powders
9.4.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms
9.4.1.4 Granules
9.4.1.4.1 Increasing adoption of modified-release and pediatric-friendly formulations driving granules market growth
9.4.1.5 Lozenges
9.4.1.5.1 Prolonged drug release and localized action enhancing adoption of lozenges
9.4.2 LIQUID ORAL DRUGS
9.4.2.1 Syrups
9.4.2.1.1 Easy administration to patients with swallowing difficulties
9.4.2.2 Solutions
9.4.2.2.1 Geriatric and pediatric patients generally prefer solutions
9.4.2.3 Emulsions
9.4.2.3.1 Emulsions offer enhanced solubility and stability with ease of administration
9.4.2.4 Suspensions
9.4.2.4.1 Increasing demand for pediatric and geriatric-friendly formulations is driving the oral suspension market growth
9.4.2.5 Elixirs
9.4.2.5.1 Elixirs are a preferred choice for the pediatric population
9.4.3 SEMI-SOLID ORAL DRUGS
9.4.3.1 Gels
9.4.3.1.1 Gels are used for controlled drug release
9.4.3.2 Pastes
9.4.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis
9.5 TOPICAL DRUG DELIVERY
9.5.1 SEMI-SOLID FORMULATIONS
9.5.1.1 Ointments
9.5.1.1.1 Ointments are widely used in analgesic indications
9.5.1.2 Creams
9.5.1.2.1 Creams are either water-in-oil or oil-in-water emulsions
9.5.1.3 Lotions
9.5.1.3.1 Easy administration of lotions to drive demand among end users
9.5.1.4 Gels
9.5.1.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels
9.5.1.5 Pastes
9.5.1.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation
9.5.2 LIQUID FORMULATIONS
9.5.2.1 Suspensions
9.5.2.1.1 Higher rate of bioavailability and controlled onset of action to drive market
9.5.2.2 Emulsions
9.5.2.2.1 Improved spreadability, stability, and controlled release of active ingredients
9.5.2.3 Solutions
9.5.2.3.1 Uniform & rapid drug delivery to boost demand
9.5.3 SOLID FORMULATIONS
9.5.3.1 Powders
9.5.3.1.1 Powders have a very fine particle size that covers a large surface area per unit weight
9.5.3.2 Suppositories
9.5.3.2.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug
9.5.4 FILMS
9.5.4.1 Next-generation advancements to boost demand
9.5.5 TRANSDERMAL FORMULATIONS
9.5.5.1 Transdermal patches
9.5.5.1.1 Transdermal patches prevent premature metabolization of drugs through the liver
9.5.6 TRANSDERMAL GELS
9.5.6.1 Rapid release of drugs to fuel uptake
9.5.7 TRANSDERMAL SPRAYS
9.5.7.1 Targeted approach to boost demand
9.6 OCULAR DRUG DELIVERY
9.6.1 LIQUID FORMULATIONS
9.6.1.1 Eye drops
9.6.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth
9.6.1.2 Liquid sprays
9.6.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops
9.6.2 SEMI-SOLID FORMULATIONS
9.6.2.1 Gels
9.6.2.1.1 High viscosity of drugs, prolonged drug release, and ease of drug administration contribute to market growth
9.6.2.2 Eye ointments
9.6.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug
9.6.3 OCULAR DEVICES
9.6.3.1 Drug-coated contact lenses
9.6.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses
9.6.3.2 Ocular inserts
9.6.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye
9.7 PULMONARY DRUG DELIVERY
9.7.1 PULMONARY DRUG DELIVERY DEVICE
9.7.1.1 Metered-dose Inhalers
9.7.1.2 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath
9.7.1.2.1 Global Volume Analysis of Metered Dose Inhalers, By Region, 2024–2031 (Ten thousand units)
9.7.1.3 Dry Powder Inhalers
9.7.1.3.1 Dry powder inhaler formulations are chemically more stable than their counterparts
9.7.1.3.2 Global Volume Analysis of Dry Powder Inhalers, By Region, 2024–2031 (Ten thousand units)
9.7.1.4 Nebulizers
9.7.1.4.1 Global Volume Analysis of Nebulizers, By Region, 2024–2031 (Ten thousand units)
9.7.1.4.2 Jet nebulizers
9.7.1.4.2.1 Jet nebulizers account for the largest share of the nebulizers market
9.7.1.4.3 Ultrasonic nebulizers
9.7.1.4.3.1 Ultrasonic nebulizers are easy to use and comfortable to handle
9.7.1.4.4 Soft mist nebulizers
9.7.1.4.4.1 Soft mist nebulizers are preferred for the treatment of severe COPD
9.7.2 PULMONARY DRUG DELIVERY FORMULATION
9.7.2.1 Suspension Aerosol
9.7.2.2 Suspension Aerosols Enable Delivery of Insoluble Drug Formulations
9.7.2.3 Solution Aerosol
9.7.2.3.1 Solution Aerosols Support Uniform Drug Distribution and Formulation Flexibility
9.7.3 DRY POWDER FORMULATIONS
9.8 NASAL DRUG DELIVERY
9.8.1 NASAL DROPS & LIQUIDS
9.8.1.1 Nasal drops are considered more efficient than nasal sprays
9.8.2 NASAL SPRAYS
9.8.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing
9.8.3 NASAL POWDERS
9.8.3.1 Absence of preservatives and superior stability of formulations are some advantages associated with nasal powders
9.9 TRANSMUCOSAL DRUG DELIVERY
9.9.1 ORAL FORMULATIONS
9.9.1.1 Buccal drug delivery
9.9.1.1.1 Buccal drug delivery system is suitable for local and systemic therapies
9.9.1.2 Sublingual drug delivery
9.9.1.2.1 Higher rate of drug absorption compared to oral route drives adoption
9.9.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES
9.9.2.1 Rectal transmucosal drug delivery
9.9.2.1.1 Enhanced bioavailability and bypassing first-pass metabolism
9.9.2.2 Vaginal transmucosal drug delivery
9.9.2.2.1 Higher permeability and direct access to target systems drive adoption
9.10 IMPLANTABLE DRUG DELIVERY
9.10.1 ACTIVE IMPLANTABLE DRUG DELIVERY
9.10.1.1 Active implantable devices are used for diagnostic monitoring, body fluid transportation, and ionizing radiation
9.10.2 PASSIVE IMPLANTABLE DRUG DELIVERY
9.10.2.1 Passive implantable drug delivery systems offer a means to achieve targeted drug delivery
9.11 OTIC DRUG DELIVERY
9.11.1 EAR DROPS
9.11.1.1 Increasing prevalence of ear infections and demand for localized treatment are driving ear drops segment growth
9.11.2 OTIC SPRAYS
9.11.2.1 Growing demand for uniform drug distribution and improved patient convenience driving adoption
10 PHARMACEUTICAL DRUG DELIVERY, BY APPLICATION
10.1 INTRODUCTION
10.2 INJECTABLE DRUG DELIVERY
10.2.1 METABOLIC DISORDERS (DIABETES, OBESITY)
10.2.1.1 Rising burden of diabetes and obesity driving strong adoption of injectable drug delivery
10.2.2 CANCER
10.2.2.1 Rising prevalence of cancer and growing availability of therapeutics to drive market
10.2.3 IMMUNOLOGICAL & AUTOIMMUNE DISEASES
10.2.3.1 Increased focus on early-stage diagnosis and treatment to propel segment growth
10.2.4 INFECTIOUS DISEASES
10.2.4.1 Increasing use of liposomes to aid segment growth
10.2.5 OTHER INJECTABLE DRUG DELIVERY APPLICATIONS
10.3 ORAL DRUG DELIVERY
10.3.1 CARDIOVASCULAR DISEASES
10.3.1.1 High prevalence of CVDs and widespread use of oral therapies drive market
10.3.2 METABOLIC DISORDERS (DIABETES, OBESITY)
10.3.2.1 Growing preference for self-injection devices over traditional syringes to augment market growth
10.3.3 CNS DISORDERS
10.3.3.1 Chronic nature of CNS disorders and long-term therapy needs driving oral drug delivery adoption
10.3.4 INFECTIOUS DISEASES
10.3.4.1 High global infection burden and outpatient treatment trends driving oral drug delivery adoption
10.3.5 ONCOLOGY (ORAL THERAPIES)
10.3.5.1 Shift toward targeted therapies and at-home treatment driving oral drug delivery in oncology
10.3.6 OTHER ORAL DRUG DELIVERY APPLICATIONS
10.4 TOPICAL DRUG DELIVERY
10.4.1 DERMATOLOGICAL DISORDERS
10.4.1.1 High prevalence of skin disorders driving strong demand for topical drug delivery
10.4.2 PAIN MANAGEMENT
10.4.2.1 Localized relief and reduced systemic side-effects driving topical drug delivery in pain management
10.4.3 WOUND CARE
10.4.3.1 Rising incidence of chronic wounds and surgical procedures driving topical drug delivery in wound care
10.5 OCULAR DRUG DELIVERY
10.5.1 RETINAL DISORDERS
10.5.1.1 Rising prevalence of retinal diseases and biologics adoption driving growth in the retinal disorders segment
10.5.2 GLAUCOMA
10.5.2.1 High prevalence and lifelong therapy requirements driving ocular drug delivery in glaucoma
10.5.3 EYE INFECTIOUS DISEASES
10.5.3.1 High incidence of ocular infections and need for rapid localized therapy driving eye infectious diseases segment
10.5.4 OTHER OCULAR DRUG DELIVERY APPLICATIONS
10.6 PULMONARY DRUG DELIVERY
10.6.1 ASTHMA
10.6.1.1 High global asthma prevalence and lifelong inhalation therapy driving pulmonary drug delivery demand
10.6.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
10.6.2.1 Chronic disease burden and high reliance on inhalation therapies driving pulmonary drug delivery in COPD
10.6.3 PULMONARY INFECTIONS
10.6.3.1 High burden of respiratory infections and need for rapid drug action driving pulmonary drug delivery in pulmonary infections
10.6.4 OTHER PULMONARY DRUG DELIVERY APPLICATIONS
10.7 NASAL DRUG DELIVERY
10.7.1 ALLERGIC RHINITIS
10.7.1.1 High prevalence of allergic conditions driving nasal drug delivery in allergic rhinitis
10.7.2 SINUSITIS
10.7.2.1 High prevalence of sinus infections and need for targeted therapy driving nasal drug delivery in sinusitis
10.7.3 OTHER NASAL DRUG DELIVERY APPLICATIONS
10.8 TRANSMUCOSAL DRUG DELIVERY
10.8.1 PAIN MANAGEMENT
10.8.1.1 Rapid onset and improved patient compliance driving transmucosal drug delivery in pain management
10.8.2 HORMONE THERAPY
10.8.2.1 Need for controlled hormone delivery and long-term therapy driving transmucosal drug delivery in hormonal therapy
10.8.3 INFECTIOUS DISEASES
10.8.3.1 Targeted local therapy and improved patient compliance driving transmucosal drug delivery in infectious diseases
10.8.4 OTHER TRANSMUCOSAL DRUG DELIVERY APPLICATIONS
10.9 IMPLANTABLE DRUG DELIVERY
10.9.1 HORMONAL THERAPY/CONTRACEPTION
10.9.1.1 Long-acting reversible contraceptives and sustained hormone delivery driving market
10.9.2 CANCER
10.9.2.1 Targeted therapy and sustained drug release driving implantable drug delivery in cancer
10.9.3 OTHER IMPLANTABLE DRUG DELIVERY APPLICATIONS
10.10 OTIC DRUG DELIVERY
10.10.1 EAR INFECTIONS
10.10.1.1 High incidence of otitis and pediatric burden driving otic drug delivery in ear infections
10.10.2 CERUMEN REMOVAL
10.10.2.1 Growing demand for ear hygiene and non-invasive treatments driving otic drug delivery in cerumen removal
10.10.3 OTHER OTIC DRUG DELIVERY APPLICATIONS
11 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE
11.1 INTRODUCTION
11.2 FORMULATIONS, BY FACILITY OF USE
11.2.1 HOSPITALS
11.2.1.1 Increased hospital demand for complex drug delivery boosts market uptake
11.2.2 HOME CARE SETTINGS
11.2.2.1 Rising preference for self-administration of medicine to drive market
11.2.3 AMBULATORY SURGERY CENTERS/CLINICS
11.2.3.1 Shift toward cost-effective outpatient care driving adoption of drug delivery systems
11.2.4 DIAGNOSTIC CENTERS
11.2.4.1 Rising prevalence of chronic diseases to support market growth
11.2.5 LONG-TERM CARE SETTINGS
11.2.5.1 Growing elderly population and chronic disease burden to drive market
11.2.6 OTHER FACILITIES OF USE
11.3 DEVICES, BY FACILITY OF USE
11.3.1 PHARMACEUTICAL COMPANIES
11.3.1.1 Increasing focus on advanced drug delivery systems driving market growth
11.3.2 BIOTECHNOLOGY COMPANIES
11.3.2.1 Enabling complex biologics delivery and decentralized care
11.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS)
11.3.3.1 Fueling innovation through cost-effective and scalable manufacturing solutions
12 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
12.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031
12.2.3 US
12.2.3.1 US to dominate North American pharmaceutical drug delivery market
12.2.4 CANADA
12.2.4.1 Government support for research and the prevalence of chronic diseases to drive the market in Canada
12.3 EUROPE
12.3.1 EUROPE: MACROECONOMIC OUTLOOK
12.3.2 EUROPE: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031
12.3.3 GERMANY
12.3.3.1 Growing focus of pharmaceutical companies on the development of various drug delivery products to drive market
12.3.4 UK
12.3.4.1 NHS support and growing access to cost-effective pen needles to drive the market
12.3.5 FRANCE
12.3.5.1 Presence of leading pharmaceutical companies, along with the increasing prevalence of chronic diseases, to drive market growth in France
12.3.6 ITALY
12.3.6.1 Increasing focus on clinical research and growing popularity of branded drugs to drive demand for pharmaceutical drug manufacturing
12.3.7 DENMARK
12.3.7.1 Strong R&D ecosystem, biologics innovation, and export-driven pharmaceutical manufacturing to drive demand for pharmaceutical drug delivery
12.3.8 SWEDEN
12.3.8.1 Strong life sciences ecosystem, biologics innovation, and government-backed healthcare system to drive demand for pharmaceutical drug delivery
12.3.9 SPAIN
12.3.9.1 Increase in biologics production to support market growth
12.3.10 NETHERLANDS
12.3.10.1 Enhancing patient care through innovation and collaboration to drive market growth
12.3.11 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031
12.4.3 CHINA
12.4.3.1 A high diabetic population and rising prevalence of chronic diseases contribute to China’s large demand
12.4.4 JAPAN
12.4.4.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan
12.4.5 INDIA
12.4.5.1 Growing generic demand and rising government initiatives to drive market
12.4.6 AUSTRALIA
12.4.6.1 Rising investment and a favorable tax environment to support growth
12.4.7 SOUTH KOREA
12.4.7.1 Strong government support and investments in healthcare & biopharmaceuticals to propel growth
12.4.8 NEW ZEALAND
12.4.8.1 Strong public healthcare system, rising biologics adoption, and focus on advanced therapies to drive demand
12.4.9 THAILAND
12.4.9.1 Regulatory reforms and healthcare initiatives to fuel market growth
12.4.10 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
12.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
12.5.3 LATIN AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031
12.5.4 BRAZIL
12.5.4.1 Brazil attracting multinational pharmaceutical companies
12.5.5 MEXICO
12.5.5.1 Growth and diversification in Mexico's pharmaceutical exports
12.5.6 ARGENTINA
12.5.6.1 Expanding domestic pharmaceutical production, increasing chronic disease burden, and growing biologics adoption to drive demand
12.5.7 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
12.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024–2031
12.6.3 GCC COUNTRIES
12.6.3.1 Kingdom of Saudi Arabia (KSA)
12.6.3.1.1 Healthcare reforms and global partnerships fuel pharmaceutical market growth
12.6.3.2 United Arab Emirates (UAE)
12.6.3.2.1 Government supports and growing local manufacturing to drive market growth
12.6.3.3 Rest of GCC Countries
12.6.4 REST OF MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3 REVENUE ANALYSIS, 2023–2025
13.3.1 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS
13.3.2 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS
13.4 MARKET SHARE ANALYSIS, 2025
13.4.1 GLOBAL INJECTABLE DRUG DELIVERY MANUFACTURERS
13.4.1.1 Global Injectable Drug Delivery Device Manufacturers
13.4.1.2 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
13.4.1.2.1 US Injectable Drug Delivery Formulation Manufacturers
13.4.1.3 Europe Injectable drug delivery formulation manufacturers
13.4.2 GLOBAL ORAL DRUG DELIVERY MANUFACTURERS
13.4.2.1 US oral drug delivery formulation manufacturers
13.4.2.2 Europe oral drug delivery manufacturers
13.4.3 GLOBAL TOPICAL DRUG DELIVERY MANUFACTURERS
13.4.3.1 US Topical Drug Delivery Formulation Manufacturers
13.4.3.2 Europe Topical Drug Delivery Manufacturers
13.5 BRAND/PRODUCT COMPARISON
13.6 R&D EXPENDITURE OF KEY PLAYERS
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.7.1 COMPANY VALUATION
13.7.2 FINANCIAL METRICS
13.8 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025
13.8.1 STARS
13.8.2 EMERGING LEADERS
13.8.3 PERVASIVE PLAYERS
13.8.4 PARTICIPANTS
13.8.5 COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025
13.8.5.1 Company footprint
13.8.5.2 Region footprint
13.8.5.3 Product type footprint
13.8.5.4 Usability footprint
13.9 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025
13.9.1 STARS
13.9.2 EMERGING LEADERS
13.9.3 PERVASIVE PLAYERS
13.9.4 PARTICIPANTS
13.9.5 COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025
13.9.5.1 Company footprint
13.9.5.2 Region footprint
13.9.5.3 Route of administration footprint
13.9.5.4 Therapeutic application footprint
13.10 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025
13.10.1 PROGRESSIVE COMPANIES
13.10.2 DYNAMIC COMPANIES
13.10.3 STARTING BLOCKS
13.10.4 RESPONSIVE COMPANIES
13.10.5 COMPETITIVE BENCHMARKING: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025
13.10.5.1 Detailed list of key startups/SMEs
13.10.5.2 Competitive benchmarking of startups/SMEs
13.11 COMPETITIVE SCENARIO
13.11.1 PRODUCT APPROVALS AND LAUNCHES
13.11.2 DEALS
13.11.3 EXPANSIONS
13.11.4 OTHER DEVELOPMENTS
LIST OF TABLES
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE, 2024
TABLE 3 KEY DEVELOPMENTS IN PRE-FILLED SYRINGES AND PEN INJECTORS, 2024–2025
TABLE 4 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20–79 YEARS), 2021 VS. 2045
TABLE 5 KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES
TABLE 6 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (IN USD BILLION)
TABLE 8 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025
TABLE 9 AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025
TABLE 10 AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025
TABLE 11 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 12 AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 13 AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 14 AVERAGE SELLING PRICE TREND OF PULMONARY DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 15 AVERAGE SELLING PRICE TREND OF OCULAR DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 16 AVERAGE SELLING PRICE TREND OF NASAL DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 17 IMPORT DATA FOR HS CODE 9021, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 18 EXPORT DATA FOR HS CODE 3004, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 19 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 20 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 21 PHARMACEUTICAL DRUG DELIVERY MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027
TABLE 22 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE
TABLE 23 CASE STUDY 1: MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM
TABLE 24 CASE STUDY 2: YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY
TABLE 25 CASE STUDY 3: ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE
TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 27 KEY PRODUCT-RELATED TARIFFS EFFECTIVE PHARMACEUTICAL DRUG DELIVERY PRODUCTS
TABLE 28 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA
TABLE 29 ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA
TABLE 30 EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK
TABLE 31 LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO
TABLE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: MAJOR PATENTS
TABLE 33 KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL DRUG DELIVERY MARKET
TABLE 34 REGULATORY SCENARIO BY COUNTRY
TABLE 35 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 36 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 37 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 38 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 39 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 40 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 41 PHARMACEUTICAL DRUG DELIVERY MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (DEVICES)
TABLE 42 PHARMACEUTICAL DRUG DELIVERY MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (FORMULATIONS)
TABLE 43 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 44 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION)
TABLE 45 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 46 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 47 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES
TABLE 48 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 49 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY,
024–2031 (USD BILLION)
TABLE 50 KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES
TABLE 51 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 52 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 53 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2024–2031 (USD BILLION)
TABLE 54 KEY PLAYERS PROVIDING CONVENTIONAL GLASS INJECTION DEVICES
TABLE 55 CONVENTIONAL GLASS INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 56 KEY PLAYERS PROVIDING CONVENTIONAL PLASTIC INJECTION DEVICES
TABLE 57 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 58 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2024–2031 (USD BILLION)
TABLE 59 KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES
TABLE 60 CONVENTIONAL REUSABLE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 61 KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES
TABLE 62 CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 63 CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 64 KEY PLAYERS PROVIDING FILLABLE SYRINGES
TABLE 65 FILLABLE SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 66 KEY PLAYERS PROVIDING PREFILLED SYRINGES
TABLE 67 PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 68 KEY PLAYERS PROVIDING SELF-INJECTION DEVICES
TABLE 69 SELF-INJECTION DEVICES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 70 SELF-INJECTION DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD BILLION)
TABLE 71 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 72 KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS
TABLE 73 NEEDLE-FREE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 74 KEY PLAYERS PROVIDING AUTOINJECTORS
TABLE 75 AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 76 KEY PLAYERS PROVIDING PEN INJECTORS
TABLE 77 PEN INJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 78 KEY PLAYERS PROVIDING WEARABLE INJECTORS
TABLE 79 WEARABLE INJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 80 KEY PLAYERS PROVIDING OTHER INJECTABLE DEVICES
TABLE 81 OTHER INJECTABLE DRUG DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 82 KEY PLAYERS PROVIDING FORMULATIONS
TABLE 83 FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 84 FORMULATIONS MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 85 KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS
TABLE 86 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 87 KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS
TABLE 88 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 89 KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS
TABLE 90 LONG-ACTING FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 91 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION)
TABLE 92 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 93 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 94 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 95 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY, BY COUNTRY 2024–2031 (USD BILLION)
TABLE 96 ORAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 97 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 98 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 99 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 100 TABLETS MARKET, BY REGION, 2024–2031 (USD BILLION)
TABLE 101 CAPSULES MARKET, BY REGION, 2024–2031 (USD BILLION)
TABLE 102 POWDERS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 103 GRANULES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 104 LOZENGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 105 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 106 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 ORAL SYRUPS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 108 ORAL SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 109 ORAL EMULSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 110 ORAL SUSPENSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 111 ORAL ELIXIRS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 112 ORAL DRUG DELIVERY MARKET FOR SEMI-SOLID DRUGS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 113 ORAL DRUG DELIVERY MARKET FOR SEMI-SOLID DRUGS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 114 ORAL GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 115 ORAL PASTES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 116 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 117 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 KEY SEMI-SOLID FORMULATIONS CURRENTLY AVAILABLE
TABLE 119 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 120 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 121 KEY OINTMENTS CURRENTLY OFFERED
TABLE 122 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 123 KEY CREAMS CURRENTLY AVAILABLE
TABLE 124 TOPICAL CREAMS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 125 KEY PLAYERS PROVIDING LOTIONS
TABLE 126 TOPICAL LOTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 127 KEY PLAYERS PROVIDING GELS
TABLE 128 TOPICAL GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 129 KEY PASTES CURRENTLY AVAILABLE
TABLE 130 TOPICAL PASTES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 131 KEY LIQUID FORMULATIONS CURRENTLY AVAILABLE
TABLE 132 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 133 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 134 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 135 TOPICAL EMULSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 136 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 137 KEY SOLID FORMULATIONS CURRENTLY AVAILABLE
TABLE 138 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 139 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 140 KEY PLAYERS PROVIDING POWDERS
TABLE 141 TOPICAL POWDERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 KEY PLAYERS PROVIDING SUPPOSITORIES
TABLE 143 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 KEY PLAYERS PROVIDING FILMS
TABLE 145 TOPICAL FILMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 KEY TRANSDERMAL PRODUCTS CURRENTLY AVAILABLE
TABLE 147 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 148 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 149 KEY PLAYERS PROVIDING TRANSDERMAL PATCHES
TABLE 150 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 KEY PLAYERS PROVIDING TRANSDERMAL GELS
TABLE 152 TRANSDERMAL GELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 KEY PLAYERS PROVIDING TRANSDERMAL SPRAYS
TABLE 154 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 156 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 157 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 158 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 159 COMMERCIALLY AVAILABLE EYE DROPS
TABLE 160 EYE DROPS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 161 LIQUID SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 162 OCULAR DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 163 OCULAR DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 164 OCULAR GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 165 EYE OINTMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2024–2031 (USD BILLION)
TABLE 167 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 168 DRUG-COATED CONTACT LENSES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 169 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 OCULAR INSERTS MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 171 OCULAR INSERTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 173 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 174 PULMONARY DRUG DELIVERY DEVICE MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 175 PULMONARY DRUG DELIVERY DEVICE MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 176 PULMONARY DRUG DELIVERY MARKET FOR METERED DOSE INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 177 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 178 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 179 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 180 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 181 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 182 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 183 JET NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 PULMONARY DRUG DELIVERY FORMULATION MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 187 PULMONARY DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 188 PULMONARY DRUG DELIVERY MARKET FOR SUSPENSION AEROSOL, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 189 PULMONARY DRUG DELIVERY MARKET FOR SOLUTION AEROSOL, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 190 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 191 NASAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 192 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 193 NASAL DROPS & LIQUIDS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 194 NASAL SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 195 NASAL POWDERS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 196 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 197 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 198 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 199 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 200 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 201 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 202 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, BY TYPE, 2024–2031 (USD BILLION)
TABLE 203 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 205 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 207 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 208 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 210 OTIC DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 211 OTIC DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 212 OTIC DRUG DELIVERY MARKET FOR EAR DROPS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 OTIC DRUG DELIVERY MARKET BY OTIC SPRAYS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 214 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS
TABLE 215 INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 216 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 217 INJECTABLE DRUG DELIVERY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 218 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD BILLION
TABLE 219 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNOLOGICAL & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 220 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 221 INJECTABLE DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 222 ORAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 223 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 224 ORAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 225 ORAL DRUG DELIVERY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 226 ORAL DRUG DELIVERY MARKET FOR CNS DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 227 ORAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 228 ORAL DRUG DELIVERY MARKET FOR ONCOLOGY (ORAL THERAPIES), BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 229 ORAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 230 TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 231 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 232 TOPICAL DRUG DELIVERY MARKET FOR DERMATOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 233 TOPICAL DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 234 TOPICAL DRUG DELIVERY MARKET FOR WOUND CARE, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 235 OCULAR DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION
TABLE 236 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 237 OCULAR DRUG DELIVERY MARKET FOR RETINAL DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 238 OCULAR DRUG DELIVERY MARKET FOR GLAUCOMA, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 239 OCULAR DRUG DELIVERY MARKET FOR EYE INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 240 OCULAR DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 241 PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION
TABLE 242 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 243 PULMONARY DRUG DELIVERY MARKET FOR ASTHMA, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 244 PULMONARY DRUG DELIVERY MARKET FOR COPD, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 245 PULMONARY DRUG DELIVERY MARKET FOR PULMONARY INFECTIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 246 PULMONARY DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 247 NASAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 248 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 249 NASAL DRUG DELIVERY MARKET FOR ALLERGIC RHINITIS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 250 NASAL DRUG DELIVERY MARKET FOR SINUSITIS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 251 NASAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 252 TRANSMUCOSAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 253 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 254 TRANSMUCOSAL DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 255 TRANSMUCOSAL DRUG DELIVERY MARKET FOR HORMONE THERAPY, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 256 TRANSMUCOSAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 257 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 258 IMPLANTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 259 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 260 IMPLANTABLE DRUG DELIVERY MARKET FOR HORMONAL THERAPY/CONTRACEPTION, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 261 IMPLANTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 262 IMPLANTABLE DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 263 OTIC DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 264 OTIC DRUG DELIVERY MARKET, BY, APPLICATION, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 265 OTIC DRUG DELIVERY MARKET FOR EAR INFECTIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 266 OTIC DRUG DELIVERY MARKET FOR CERUMEN REMOVAL, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 267 OTIC DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 268 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION)
TABLE 269 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION)
TABLE 270 FACILITY OF USE: PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR LONG-TERM CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION)
TABLE 278 FACILITY OF USE: PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2024–2031 (USD BILLION)
TABLE 283 NORTH AMERICA: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS)
TABLE 284 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024-2031 (USD BILLION)
TABLE 285 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION)
TABLE 286 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 287 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION)
TABLE 288 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY MATERIAL, 2024-2031 (USD BILLION)
TABLE 289 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY USABILITY, 2024-2031 (USD BILLION)
TABLE 290 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION)
TABLE 291 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION)
TABLE 292 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 293 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION)
TABLE 294 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 295 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 296 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 297 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 298 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 299 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 300 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 301 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 302 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 303 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 304 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 305 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 306 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 307 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION)
TABLE 308 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 309 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION)
TABLE 310 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION)
TABLE 311 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION)
TABLE 312 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 313 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 314 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 315 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION)
TABLE 316 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 317 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 318 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 319 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 320 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 321 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 322 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 323 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 324 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 325 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 326 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 327 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION)
TABLE 328 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION)
TABLE 329 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION)
TABLE 330 US: KEY MACROINDICATORS
TABLE 331 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION)
TABLE 332 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 333 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION)
TABLE 334 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY MATERIAL, 2024-2031 (USD BILLION)
TABLE 335 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, BY USABILITY, 2024-2031 (USD BILLION)
TABLE 336 US PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2024-2031 (USD BILLION)
TABLE 337 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION)
TABLE 338 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 339 US PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION)
TABLE 340 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 341 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 342 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 343 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 344 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 345 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 346 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 347 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 348 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 349 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 350 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 351 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 352 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 353 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION)
TABLE 354 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 355 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION)
TABLE 356 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION)
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE, 2024
TABLE 3 KEY DEVELOPMENTS IN PRE-FILLED SYRINGES AND PEN INJECTORS, 2024–2025
TABLE 4 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20–79 YEARS), 2021 VS. 2045
TABLE 5 KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES
TABLE 6 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (IN USD BILLION)
TABLE 8 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025
TABLE 9 AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025
TABLE 10 AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025
TABLE 11 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 12 AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 13 AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 14 AVERAGE SELLING PRICE TREND OF PULMONARY DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 15 AVERAGE SELLING PRICE TREND OF OCULAR DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 16 AVERAGE SELLING PRICE TREND OF NASAL DRUG DELIVERY PRODUCTS, BY REGION, 2023?2025
TABLE 17 IMPORT DATA FOR HS CODE 9021, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 18 EXPORT DATA FOR HS CODE 3004, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 19 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 20 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 21 PHARMACEUTICAL DRUG DELIVERY MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027
TABLE 22 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE
TABLE 23 CASE STUDY 1: MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM
TABLE 24 CASE STUDY 2: YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY
TABLE 25 CASE STUDY 3: ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE
TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 27 KEY PRODUCT-RELATED TARIFFS EFFECTIVE PHARMACEUTICAL DRUG DELIVERY PRODUCTS
TABLE 28 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA
TABLE 29 ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA
TABLE 30 EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK
TABLE 31 LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO
TABLE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: MAJOR PATENTS
TABLE 33 KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL DRUG DELIVERY MARKET
TABLE 34 REGULATORY SCENARIO BY COUNTRY
TABLE 35 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 36 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 37 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 38 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 39 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 40 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 41 PHARMACEUTICAL DRUG DELIVERY MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (DEVICES)
TABLE 42 PHARMACEUTICAL DRUG DELIVERY MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (FORMULATIONS)
TABLE 43 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 44 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION)
TABLE 45 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 46 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 47 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES
TABLE 48 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 49 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY,
024–2031 (USD BILLION)
TABLE 50 KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES
TABLE 51 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 52 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 53 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2024–2031 (USD BILLION)
TABLE 54 KEY PLAYERS PROVIDING CONVENTIONAL GLASS INJECTION DEVICES
TABLE 55 CONVENTIONAL GLASS INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 56 KEY PLAYERS PROVIDING CONVENTIONAL PLASTIC INJECTION DEVICES
TABLE 57 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 58 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2024–2031 (USD BILLION)
TABLE 59 KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES
TABLE 60 CONVENTIONAL REUSABLE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 61 KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES
TABLE 62 CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 63 CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 64 KEY PLAYERS PROVIDING FILLABLE SYRINGES
TABLE 65 FILLABLE SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 66 KEY PLAYERS PROVIDING PREFILLED SYRINGES
TABLE 67 PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 68 KEY PLAYERS PROVIDING SELF-INJECTION DEVICES
TABLE 69 SELF-INJECTION DEVICES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 70 SELF-INJECTION DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD BILLION)
TABLE 71 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 72 KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS
TABLE 73 NEEDLE-FREE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 74 KEY PLAYERS PROVIDING AUTOINJECTORS
TABLE 75 AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 76 KEY PLAYERS PROVIDING PEN INJECTORS
TABLE 77 PEN INJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 78 KEY PLAYERS PROVIDING WEARABLE INJECTORS
TABLE 79 WEARABLE INJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 80 KEY PLAYERS PROVIDING OTHER INJECTABLE DEVICES
TABLE 81 OTHER INJECTABLE DRUG DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 82 KEY PLAYERS PROVIDING FORMULATIONS
TABLE 83 FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 84 FORMULATIONS MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 85 KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS
TABLE 86 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 87 KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS
TABLE 88 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 89 KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS
TABLE 90 LONG-ACTING FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 91 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION)
TABLE 92 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 93 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 94 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 95 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY, BY COUNTRY 2024–2031 (USD BILLION)
TABLE 96 ORAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 97 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 98 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 99 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 100 TABLETS MARKET, BY REGION, 2024–2031 (USD BILLION)
TABLE 101 CAPSULES MARKET, BY REGION, 2024–2031 (USD BILLION)
TABLE 102 POWDERS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 103 GRANULES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 104 LOZENGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 105 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 106 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 ORAL SYRUPS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 108 ORAL SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 109 ORAL EMULSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 110 ORAL SUSPENSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 111 ORAL ELIXIRS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 112 ORAL DRUG DELIVERY MARKET FOR SEMI-SOLID DRUGS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 113 ORAL DRUG DELIVERY MARKET FOR SEMI-SOLID DRUGS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 114 ORAL GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 115 ORAL PASTES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 116 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 117 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 KEY SEMI-SOLID FORMULATIONS CURRENTLY AVAILABLE
TABLE 119 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 120 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 121 KEY OINTMENTS CURRENTLY OFFERED
TABLE 122 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 123 KEY CREAMS CURRENTLY AVAILABLE
TABLE 124 TOPICAL CREAMS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 125 KEY PLAYERS PROVIDING LOTIONS
TABLE 126 TOPICAL LOTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 127 KEY PLAYERS PROVIDING GELS
TABLE 128 TOPICAL GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 129 KEY PASTES CURRENTLY AVAILABLE
TABLE 130 TOPICAL PASTES MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 131 KEY LIQUID FORMULATIONS CURRENTLY AVAILABLE
TABLE 132 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 133 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 134 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 135 TOPICAL EMULSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 136 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 137 KEY SOLID FORMULATIONS CURRENTLY AVAILABLE
TABLE 138 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 139 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 140 KEY PLAYERS PROVIDING POWDERS
TABLE 141 TOPICAL POWDERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 KEY PLAYERS PROVIDING SUPPOSITORIES
TABLE 143 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 KEY PLAYERS PROVIDING FILMS
TABLE 145 TOPICAL FILMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 KEY TRANSDERMAL PRODUCTS CURRENTLY AVAILABLE
TABLE 147 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 148 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 149 KEY PLAYERS PROVIDING TRANSDERMAL PATCHES
TABLE 150 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 KEY PLAYERS PROVIDING TRANSDERMAL GELS
TABLE 152 TRANSDERMAL GELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 KEY PLAYERS PROVIDING TRANSDERMAL SPRAYS
TABLE 154 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 156 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 157 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 158 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 159 COMMERCIALLY AVAILABLE EYE DROPS
TABLE 160 EYE DROPS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 161 LIQUID SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 162 OCULAR DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 163 OCULAR DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 164 OCULAR GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 165 EYE OINTMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2024–2031 (USD BILLION)
TABLE 167 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 168 DRUG-COATED CONTACT LENSES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 169 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 OCULAR INSERTS MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 171 OCULAR INSERTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 173 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 174 PULMONARY DRUG DELIVERY DEVICE MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 175 PULMONARY DRUG DELIVERY DEVICE MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 176 PULMONARY DRUG DELIVERY MARKET FOR METERED DOSE INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 177 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 178 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 179 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 180 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)
TABLE 181 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 182 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 183 JET NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 PULMONARY DRUG DELIVERY FORMULATION MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 187 PULMONARY DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 188 PULMONARY DRUG DELIVERY MARKET FOR SUSPENSION AEROSOL, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 189 PULMONARY DRUG DELIVERY MARKET FOR SOLUTION AEROSOL, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 190 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 191 NASAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 192 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 193 NASAL DROPS & LIQUIDS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 194 NASAL SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 195 NASAL POWDERS MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 196 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 197 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 198 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION)
TABLE 199 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 200 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 201 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 202 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, BY TYPE, 2024–2031 (USD BILLION)
TABLE 203 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 205 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 207 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 208 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 210 OTIC DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION)
TABLE 211 OTIC DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 212 OTIC DRUG DELIVERY MARKET FOR EAR DROPS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 OTIC DRUG DELIVERY MARKET BY OTIC SPRAYS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 214 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS
TABLE 215 INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 216 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 217 INJECTABLE DRUG DELIVERY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 218 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD BILLION
TABLE 219 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNOLOGICAL & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 220 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 221 INJECTABLE DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 222 ORAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 223 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 224 ORAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 225 ORAL DRUG DELIVERY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 226 ORAL DRUG DELIVERY MARKET FOR CNS DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 227 ORAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 228 ORAL DRUG DELIVERY MARKET FOR ONCOLOGY (ORAL THERAPIES), BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 229 ORAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 230 TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 231 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 232 TOPICAL DRUG DELIVERY MARKET FOR DERMATOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 233 TOPICAL DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 234 TOPICAL DRUG DELIVERY MARKET FOR WOUND CARE, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 235 OCULAR DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION
TABLE 236 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 237 OCULAR DRUG DELIVERY MARKET FOR RETINAL DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 238 OCULAR DRUG DELIVERY MARKET FOR GLAUCOMA, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 239 OCULAR DRUG DELIVERY MARKET FOR EYE INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 240 OCULAR DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 241 PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION
TABLE 242 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 243 PULMONARY DRUG DELIVERY MARKET FOR ASTHMA, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 244 PULMONARY DRUG DELIVERY MARKET FOR COPD, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 245 PULMONARY DRUG DELIVERY MARKET FOR PULMONARY INFECTIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 246 PULMONARY DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 247 NASAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 248 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 249 NASAL DRUG DELIVERY MARKET FOR ALLERGIC RHINITIS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 250 NASAL DRUG DELIVERY MARKET FOR SINUSITIS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 251 NASAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 252 TRANSMUCOSAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 253 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 254 TRANSMUCOSAL DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 255 TRANSMUCOSAL DRUG DELIVERY MARKET FOR HORMONE THERAPY, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 256 TRANSMUCOSAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 257 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 258 IMPLANTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 259 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 260 IMPLANTABLE DRUG DELIVERY MARKET FOR HORMONAL THERAPY/CONTRACEPTION, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 261 IMPLANTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 262 IMPLANTABLE DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 263 OTIC DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION)
TABLE 264 OTIC DRUG DELIVERY MARKET, BY, APPLICATION, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 265 OTIC DRUG DELIVERY MARKET FOR EAR INFECTIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 266 OTIC DRUG DELIVERY MARKET FOR CERUMEN REMOVAL, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 267 OTIC DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION)
TABLE 268 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION)
TABLE 269 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION)
TABLE 270 FACILITY OF USE: PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 273 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR LONG-TERM CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION)
TABLE 278 FACILITY OF USE: PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2024–2031 (USD BILLION)
TABLE 283 NORTH AMERICA: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS)
TABLE 284 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024-2031 (USD BILLION)
TABLE 285 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION)
TABLE 286 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 287 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION)
TABLE 288 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY MATERIAL, 2024-2031 (USD BILLION)
TABLE 289 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY USABILITY, 2024-2031 (USD BILLION)
TABLE 290 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION)
TABLE 291 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION)
TABLE 292 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 293 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION)
TABLE 294 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 295 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 296 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 297 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 298 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 299 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 300 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 301 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 302 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 303 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 304 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 305 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 306 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 307 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION)
TABLE 308 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 309 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION)
TABLE 310 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION)
TABLE 311 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION)
TABLE 312 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 313 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 314 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 315 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION)
TABLE 316 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 317 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 318 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 319 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 320 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 321 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 322 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 323 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 324 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 325 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 326 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION)
TABLE 327 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION)
TABLE 328 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION)
TABLE 329 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION)
TABLE 330 US: KEY MACROINDICATORS
TABLE 331 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION)
TABLE 332 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 333 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION)
TABLE 334 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY MATERIAL, 2024-2031 (USD BILLION)
TABLE 335 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, BY USABILITY, 2024-2031 (USD BILLION)
TABLE 336 US PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2024-2031 (USD BILLION)
TABLE 337 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION)
TABLE 338 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 339 US PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION)
TABLE 340 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 341 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 342 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 343 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 344 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 345 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 346 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 347 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 348 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 349 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 350 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 351 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 352 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION)
TABLE 353 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION)
TABLE 354 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION)
TABLE 355 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION)
TABLE 356 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION)
LIST OF FIGURES
FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2020–2025
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PHARMACEUTICAL DRUG DELIVERY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 INCREASING NEED FOR PHARMACEUTICAL DRUG DELIVERY PRODUCTS TO FUEL MARKET GROWTH
FIGURE 9 PHARMACEUTICAL DRUG DELIVERY SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 10 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 BIOPHARMACEUTICAL R&D SPENDING (2020–2026)
FIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 16 PHARMACEUTICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 PHARMACEUTICAL DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 19 PHARMACEUTICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 20 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2024–2032
FIGURE 21 PHARMACEUTICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2015–APRIL 2026)
FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2015–APRIL 2026)
FIGURE 23 AI USE CASES
FIGURE 24 KEY STAKEHOLDERS IN BUYING PROCESS FOR PHARMACEUTICAL DRUG DELIVERY DEVICES
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACEUTICAL DRUG DELIVERY FORMULATIONS
FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 27 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2025)
FIGURE 28 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
FIGURE 30 REVENUE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2023?2025 1010
FIGURE 31 REVENUE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2023?2025 1011
FIGURE 32 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1012
FIGURE 33 RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1013
FIGURE 34 GLOBAL MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1014
FIGURE 35 RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1016
FIGURE 36 US MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1016
FIGURE 37 EUROPE MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1017
FIGURE 38 GLOBAL MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY MANUFACTURERS, 2025 1018
FIGURE 39 US MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1019
FIGURE 40 EUROPE MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY MANUFACTURERS, 2025 1020
FIGURE 41 GLOBAL MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1021
FIGURE 42 US MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1022
FIGURE 43 EUROPE MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1023
FIGURE 44 PHARMACEUTICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON 1025
FIGURE 45 R&D EXPENDITURE OF KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2023?2025 1026
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 1026
FIGURE 47 YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 1027
FIGURE 48 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS (2025) 1028
FIGURE 49 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: COMPANY FOOTPRINT 1029
FIGURE 50 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS (2025) 1032
FIGURE 51 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: COMPANY FOOTPRINT 1033
FIGURE 52 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES), 2025 1038
FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025) 1045
FIGURE 54 NOVARTIS AG: COMPANY SNAPSHOT (2025) 1059
FIGURE 55 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 1070
FIGURE 56 PFIZER INC.: COMPANY SNAPSHOT (2025) 1081
FIGURE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 1094
FIGURE 58 GSK PLC.: COMPANY SNAPSHOT (2025) 1104
FIGURE 59 ABBVIE, INC.: COMPANY SNAPSHOT (2025) 1117
FIGURE 60 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 1129
FIGURE 61 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2025) 1142
FIGURE 62 BAYER AG: COMPANY SNAPSHOT (2025) 1148
FIGURE 63 AMGEN INC.: COMPANY SNAPSHOT (2025) 1160
FIGURE 64 ASTRAZENECA: COMPANY SNAPSHOT (2025) 1167
FIGURE 65 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025) 1181
FIGURE 66 BD: COMPANY SNAPSHOT (2025) 1204
FIGURE 67 CARDINAL HEALTH: COMPANY SNAPSHOT (2024) 1210
FIGURE 68 B. BRAUN SE: COMPANY SNAPSHOT (2025) 1214
FIGURE 69 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 1217
FIGURE 70 NIPRO: COMPANY SNAPSHOT (2025) 1221
FIGURE 71 STEVANATO GROUP: COMPANY SNAPSHOT (2025) 1224
FIGURE 72 GERRESHEIMER AG: COMPANY SNAPSHOT (2025) 1229
FIGURE 73 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2025) 1234
FIGURE 74 YPSOMED: COMPANY SNAPSHOT (2025) 1238
FIGURE 75 PHARMACEUTICAL DRUG DELIVERY MARKET: RESEARCH DESIGN 1246
FIGURE 76 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 1251
FIGURE 77 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 1252
FIGURE 78 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 1252
FIGURE 79 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 1253
FIGURE 80 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 1254
FIGURE 81 REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON (2025). 1255
FIGURE 82 TOP-DOWN APPROACH 1256
FIGURE 83 BOTTOM-UP APPROACH 1256
FIGURE 84 DEMAND-SIDE APPROACH 1257
FIGURE 85 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF PHARMACEUTICAL DRUG DELIVERY MARKET (2026–2031) 1258
FIGURE 86 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 1259
FIGURE 87 DATA TRIANGULATION METHODOLOGY
FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2020–2025
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PHARMACEUTICAL DRUG DELIVERY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 INCREASING NEED FOR PHARMACEUTICAL DRUG DELIVERY PRODUCTS TO FUEL MARKET GROWTH
FIGURE 9 PHARMACEUTICAL DRUG DELIVERY SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
FIGURE 10 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 BIOPHARMACEUTICAL R&D SPENDING (2020–2026)
FIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 16 PHARMACEUTICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 PHARMACEUTICAL DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 19 PHARMACEUTICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 20 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2024–2032
FIGURE 21 PHARMACEUTICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2015–APRIL 2026)
FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2015–APRIL 2026)
FIGURE 23 AI USE CASES
FIGURE 24 KEY STAKEHOLDERS IN BUYING PROCESS FOR PHARMACEUTICAL DRUG DELIVERY DEVICES
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACEUTICAL DRUG DELIVERY FORMULATIONS
FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 27 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2025)
FIGURE 28 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
FIGURE 29 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
FIGURE 30 REVENUE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2023?2025 1010
FIGURE 31 REVENUE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2023?2025 1011
FIGURE 32 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1012
FIGURE 33 RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1013
FIGURE 34 GLOBAL MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1014
FIGURE 35 RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1016
FIGURE 36 US MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1016
FIGURE 37 EUROPE MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1017
FIGURE 38 GLOBAL MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY MANUFACTURERS, 2025 1018
FIGURE 39 US MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1019
FIGURE 40 EUROPE MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY MANUFACTURERS, 2025 1020
FIGURE 41 GLOBAL MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1021
FIGURE 42 US MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1022
FIGURE 43 EUROPE MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1023
FIGURE 44 PHARMACEUTICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON 1025
FIGURE 45 R&D EXPENDITURE OF KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2023?2025 1026
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 1026
FIGURE 47 YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 1027
FIGURE 48 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS (2025) 1028
FIGURE 49 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: COMPANY FOOTPRINT 1029
FIGURE 50 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS (2025) 1032
FIGURE 51 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: COMPANY FOOTPRINT 1033
FIGURE 52 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES), 2025 1038
FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025) 1045
FIGURE 54 NOVARTIS AG: COMPANY SNAPSHOT (2025) 1059
FIGURE 55 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 1070
FIGURE 56 PFIZER INC.: COMPANY SNAPSHOT (2025) 1081
FIGURE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 1094
FIGURE 58 GSK PLC.: COMPANY SNAPSHOT (2025) 1104
FIGURE 59 ABBVIE, INC.: COMPANY SNAPSHOT (2025) 1117
FIGURE 60 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 1129
FIGURE 61 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2025) 1142
FIGURE 62 BAYER AG: COMPANY SNAPSHOT (2025) 1148
FIGURE 63 AMGEN INC.: COMPANY SNAPSHOT (2025) 1160
FIGURE 64 ASTRAZENECA: COMPANY SNAPSHOT (2025) 1167
FIGURE 65 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025) 1181
FIGURE 66 BD: COMPANY SNAPSHOT (2025) 1204
FIGURE 67 CARDINAL HEALTH: COMPANY SNAPSHOT (2024) 1210
FIGURE 68 B. BRAUN SE: COMPANY SNAPSHOT (2025) 1214
FIGURE 69 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 1217
FIGURE 70 NIPRO: COMPANY SNAPSHOT (2025) 1221
FIGURE 71 STEVANATO GROUP: COMPANY SNAPSHOT (2025) 1224
FIGURE 72 GERRESHEIMER AG: COMPANY SNAPSHOT (2025) 1229
FIGURE 73 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2025) 1234
FIGURE 74 YPSOMED: COMPANY SNAPSHOT (2025) 1238
FIGURE 75 PHARMACEUTICAL DRUG DELIVERY MARKET: RESEARCH DESIGN 1246
FIGURE 76 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 1251
FIGURE 77 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 1252
FIGURE 78 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 1252
FIGURE 79 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 1253
FIGURE 80 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 1254
FIGURE 81 REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON (2025). 1255
FIGURE 82 TOP-DOWN APPROACH 1256
FIGURE 83 BOTTOM-UP APPROACH 1256
FIGURE 84 DEMAND-SIDE APPROACH 1257
FIGURE 85 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF PHARMACEUTICAL DRUG DELIVERY MARKET (2026–2031) 1258
FIGURE 86 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 1259
FIGURE 87 DATA TRIANGULATION METHODOLOGY
